The global Antiepileptic Drugs Market is estimated to be valued at US$ 7.01 Bn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. 

Market Overview: 

The antiepileptic drugs market comprises products that are used for the treatment and management of epilepsy. These drugs help in preventing seizures by calming down overexcited neurons in the brain. They are available in various forms such as tablets, capsules, syrups, and intravenous medications based on the condition and treatment plan designed by doctors.

Market key trends: 

One of the key trends witnessed in the antiepileptic drugs market is the continuous development of new treatment options by the players. Research is focused on developing drugs with better tolerability and efficacy profiles. Generic versions of branded drugs are also gaining popularity as they provide affordable treatment options.

Segment Analysis

The global antiepileptic drugs market is segmented into generic and branded drugs. Among these, the generic drugs segment accounts for the largest share of over 60% in the global market. This is because generic drugs are more affordable as compared to branded drugs. The demand and sales for generic antiepileptic drugs have increased significantly over the past few years due to their lower cost.

Key Takeaways 

The global antiepileptic drugs market is expected to witness high growth, exhibiting CAGR of 3.3% over the forecast period, due to increasing prevalence of epilepsy across the world. According to a report by the World Health Organization (WHO), about 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. 

Regional analysis 

North America is expected to dominate the global market over the forecast period. This is attributed to rising cases of epilepsy and advanced healthcare infrastructure in the region. Europe holds the second largest market share owing to increasing government support for epilepsy research. Asia Pacific market is likely to exhibit the fastest growth rate during the analysis period due to growing patient awareness levels and improving healthcare facilities.

Key players 

Key players operating in the antiepileptic drugs market are Novartis AG, GlaxoSmithKline Plc, Johnson Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Shanghai Zhimeng Biopharma, Inc., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., IAMA Therapeutics, Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Marinus Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.